Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A [14]

British Journal of Dermatology

Volumn 152, Issue 6, 2005, Pages 1379-1381

  Coors, E A ^a   Von Den Driesch, P ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b KLINIKUM STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; FENOFIBRATE; LEVOTHYROXINE; PSORALEN; RETINOID DERIVATIVE;

AGED; CASE REPORT; CUTANEOUS T CELL LYMPHOMA; ERYTHEMA; FATIGUE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; LETTER; MALE; MYCOSIS FUNGOIDES; NAUSEA; PRIORITY JOURNAL; PUVA;

AGED; ANTICARCINOGENIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MYCOSIS FUNGOIDES; PUVA THERAPY; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 21644452157     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06616.x     Document Type: Letter

References (11)

1. Dummer R, Kempf W, Hess Schmid M et al. Therapy of cutaneous lymphoma - current practice and future developments. Onkologie 2003; 26:366-72.
2. Zhang C, Hazarika P, Ni X et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002; 8:1234-40.
3. Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol, 2001; 137:581-93.
4. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19:2456-71.
5. Bohmeyer J, Stadler R, Kremer A et al. Bexarotene - an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. JDDG 2003; 1:785-9.
6. Stern DK, Lebwohl M. Treatment of mycosis fungoides with oral bexarotene combined with PUVA. J Drugs Dermatol 2002; 1:134-6.
7. Shapiro M, Rook AH, Lehrer MS et al. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47:956-61.
8. McGinnis KS, Shapiro M, Vittorio CC et al. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: an effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol 2003; 139:771-5.
9. Huber MA, Kunzi-Rapp K, Staib G, Scharffetter-Kochanek K. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy. J Am Acad Dermatol 2004; 50:475-6.
10. Zackheim HS. Cutaneous T-cell lymphoma: update of treatment. Dermatology 1999; 199:102-5.
11. Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA (RePUVA) in mycosis fungoides, plaque stage. Acta Derm Venereol 1989; 69:536-8. 1381-1383